Moviprep (Ascorbic Acid, Sodium Ascorbate, Potassium Chloride, Sodium Chloride, Sodium Sulfate Anhydrous, Macr)

Moviprep, an osmotic laxative used for bowel cleansing, is indicated for the following procedures:

• Colonoscopy: provides thorough bowel cleansing to enable clear visualization of the colon during the procedure.
• Sigmoidoscopy: cleanses the distal colon to facilitate examination of the sigmoid and rectal areas.
• Radiologic colon imaging: prepares the bowel for contrast studies such as CT colonography, ensuring optimal imaging quality.

• Moviprep contains polyethylene glycol, a high‑molecular‑weight polymer that is not absorbed from the gastrointestinal tract. When reconstituted, it creates an osmotic gradient that draws water into the intestinal lumen. The accompanying electrolytes (sodium, potassium, chloride, sulfate, and ascorbate) help maintain electrolyte balance, resulting in increased intestinal volume and accelerated transit, leading to complete evacuation of colonic contents.

Moviprep may cause a range of adverse reactions, most of which are related to its osmotic activity and electrolyte composition.

Common Side Effects

• Nausea: mild to moderate nausea may occur during or after ingestion.
• Abdominal bloating: feeling of fullness or distension in the abdomen.
• Abdominal pain or cramps: intermittent cramping sensations.
• Vomiting: occasional emesis, usually self‑limited.
• Thirst or dry mouth: increased fluid loss may cause mild dehydration.
• Headache: transient headache reported by some patients.

Serious or Rare Side Effects

• Severe electrolyte imbalance: significant shifts in sodium, potassium or chloride levels.
• Dehydration: marked fluid loss leading to hypotension.
• Allergic reaction: rash, itching, or anaphylaxis in rare cases.
• Colonic perforation: extremely rare but serious gastrointestinal injury.
• Acute renal failure: possible in patients with pre‑existing kidney disease.

Before prescribing Moviprep, clinicians should consider several precautionary measures to ensure safe use.

• Assess renal function: evaluate kidney status, especially in patients with chronic kidney disease.
• Monitor electrolytes: check serum sodium, potassium and chloride before and after preparation.
• Use with caution in heart failure: patients with congestive heart failure may be sensitive to fluid shifts.
• Avoid in bowel obstruction: contraindicated in known mechanical obstruction of the intestines.
• Ensure adequate fluid intake: patients should drink the recommended volume of clear liquids during the regimen.
• Store at room temperature: keep in the original packaging, protect from moisture and heat.

Moviprep can interact with other medicines, affecting electrolyte balance or gastrointestinal function.

Major Interactions (Avoid)

• Concomitant osmotic laxatives: may cause excessive fluid loss and severe electrolyte disturbances.
• Lithium therapy: altered lithium clearance can increase risk of toxicity.
• Loop or thiazide diuretics: combined effect may lead to significant electrolyte depletion.

Moderate Interactions (Monitor Closely)

• Antacids containing aluminum or magnesium: may affect absorption of electrolytes.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of renal impairment when combined with volume depletion.
• ACE inhibitors or ARBs: monitor blood pressure and electrolytes due to potential additive effects.